CytoDyn (CYDY) Operating Income (2010 - 2026)
CytoDyn's (CYDY) quarterly Operating Income came in at -$6.3 million in Q1 2026, down 57.46% YoY from -$14.8 million in Q1 2025, and up 70.94% on a QoQ basis from -$21.7 million in Q4 2025.
CytoDyn (CYDY) Operating Income (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Operating Income data on file, last reported at -$6.3 million in Q1 2026.
- Quarterly Operating Income fell 57.46% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$38.0 million (down 569.57% YoY) and the FY2025 annual result came in at $9.7 million, up 153.5% from the prior year.
- Operating Income rose to -$6.3 million in Q1 2026, from -$21.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $22.4 million in Q3 2024 to a low of -$79.0 million in Q2 2022.
- A 5-year average of -$10.6 million and a median of -$4.9 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income surged 586.49% — and 2025, when it tumbled 485.06%.
- Tracing CYDY's Operating Income over 5 years: stood at -$23.2 million in 2022, then jumped by 85.33% to -$3.4 million in 2023, then decreased by 9.09% to -$3.7 million in 2024, then plunged by 485.06% to -$21.7 million in 2025, then surged by 70.94% to -$6.3 million in 2026.
- The last three Operating Income figures came in at -$6.3 million (Q1 2026), -$21.7 million (Q4 2025), and -$4.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | -6.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -6.30 Mn |
| Nov 30, 2025 | -21.69 Mn |
| Aug 31, 2025 | -4.95 Mn |
| May 31, 2025 | -5.07 Mn |
| Feb 28, 2025 | -4.00 Mn |
| Nov 30, 2024 | -3.71 Mn |
| Aug 31, 2024 | 22.44 Mn |
| May 31, 2024 | -6.63 Mn |
| Feb 29, 2024 | -3.41 Mn |
| Nov 30, 2023 | -3.40 Mn |
| Aug 31, 2023 | -4.61 Mn |
| May 31, 2023 | -3.78 Mn |
| Feb 28, 2023 | -3.92 Mn |
| Nov 30, 2022 | -23.16 Mn |
| Aug 31, 2022 | -9.71 Mn |
| May 31, 2022 | -79.05 Mn |
| Feb 28, 2022 | -19.40 Mn |
| Nov 30, 2021 | -25.32 Mn |
| Aug 31, 2021 | -21.64 Mn |
| May 31, 2021 | -23.64 Mn |